Dr. Conn is actively involved in studies to develop new treatment strategies for Fragile X syndrome and other childhood developmental disorders. This includes basic research aimed at identifying and validating new drug targets as well as drug discovery efforts aimed at advancing new drug candidates into clinical development with industry partners.